



Caeneus Minerals Ltd  
ACN 082 593 235

Australian Securities Exchange  
Code: CAD

Ordinary shares  
2,413,226,117

Unlisted Options  
19,500,000 (exercise price of \$0.005;  
expiry date of 31 Dec 2016)  
306,150,001 (exercise price of \$0.03;  
expiry date of 27 Feb 2017)  
550,457,309 (exercise price of \$0.003;  
expiry date of 31 Dec 2020)

Board of Directors  
Mr Steven Elliott  
Mr Keith Bowker  
Mr Michael Nottas

ASX Announcement  
30 March 2016

### INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

Further to the Appendix 3B lodged on 30 March 2016 for the issue of 482,645,223 fully paid ordinary shares ("Securities") to Sophisticated Investors ("Placement"), Caeneus Minerals Ltd ("Caeneus" or "the Company") hereby provides the following information required under ASX Listing Rule 3.10.5A.

(a) The dilutive effect of the issue of the Securities on existing shareholders is as follows:

Number of shares on issue prior to the issue of the Securities: 1,930,580,894

Placement issue under Listing Rule 7.1 (289,587,134 shares)	12%
Placement issue under Listing Rule 7.1A (193,058,089 shares)	8%
Total dilution as a result of the issue of the Securities	20%

Number of shares on issue following the issue of the Securities: 2,413,226,117

Further details of the approximate percentage of the issued capital following the issue of the Securities held by the pre-issue shareholders and new shareholders are as follows. Please note that this information relates specifically in relation to the portion of shares issued under Listing Rule 7.1A (193,058,089).

Pre-issue shareholders who did <b>not</b> participate in the issue of the Securities	92.00%
Pre-issue shareholders who <b>did</b> participate in the issue of the Securities	3.62%
Participants in the issue of the Securities who were not previously shareholders	4.38%

(b) The Company considered the Placement the most efficient and expedient method for raising the funds required to achieve its stated objectives given the funding certainty. The Company also considered that there were significant benefits in introducing sophisticated investors to promote a more diverse shareholder base.

(c) No underwriting agreements were in place for the Placement; and

(d) Barclay Wells Limited was paid a fee of 6% on the funds raised pursuant to the Placement and will be issued 200,000,000 unlisted options at an issue price of \$0.00001 each with an exercise price of \$0.003 expiring 31 Dec 2020 (the unlisted options will be issued at a later date following shareholders' approval at a General Meeting of the Company).

For and on behalf of the Board

Keith Bowker  
Director/Company Secretary